Login to Your Account



India looking at noncommercial use for BMS' dasatinib

By Alfred Romann
Staff Writer

Wednesday, May 14, 2014

India is considering waiving a global patent for cancer drug dasatanib under provisions of the country's Patent Act that allow it to make the move for public noncommercial use.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription